CD79B Antibody (HM79-11): sc-59116

CD79B Antibody (HM79-11) is a hamster monoclonal IgG antibody that detects CD79B in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CD79B, also known as B29, plays a crucial role in the B cell antigen receptor (BCR) complex, where CD79B partners with CD79A to facilitate the signaling necessary for B cell activation and development. CD79B is vital for the proper functioning of the immune system, as CD79B aids in the surface expression of immunoglobulins like IgM and IgD, which are essential for antigen recognition and response. Notably, the cytoplasmic tail of CD79B contains an immunoreceptor tyrosine-based activation motif (ITAM) that is instrumental in initiating BCR signaling by recruiting and activating tyrosine kinases, thereby triggering downstream signaling pathways that lead to B cell proliferation and differentiation. CD79B′s ability to interact with various signaling molecules underscores CD79B′s importance in maintaining immune homeostasis and responding to pathogens, making anti-CD79B antibody (HM79-11) an invaluable tool for researchers studying B cell biology and related immunological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD79B Antibody (HM79-11) References:

1. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia.  |  Alfarano, A., et al. 1999. Blood. 93: 2327-35. PMID: 10090943
2. Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion.  |  Rassenti, LZ. and Kipps, TJ. 2000. Blood. 95: 2725-7. PMID: 10753858
3. Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders.  |  McCarron, KF., et al. 2000. Am J Clin Pathol. 113: 805-13. PMID: 10874881
4. Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma: a possible post transcriptional regulation.  |  Huang, X., et al. 2011. Pathol Int. 61: 122-9. PMID: 21355953
5. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.  |  Pfeifer, M., et al. 2015. Leukemia. 29: 1578-86. PMID: 25708834
6. Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.  |  Wang, JQ., et al. 2017. J Exp Med. 214: 2759-2776. PMID: 28701369
7. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.  |  Ormhøj, M., et al. 2019. Clin Cancer Res. 25: 7046-7057. PMID: 31439577
8. A New Missense Mutation in CD79B Leads to Autosomal Recessive Agammaglobulinemia in Two Siblings.  |  Genebrier, S., et al. 2021. J Clin Immunol. 41: 1356-1360. PMID: 33733381
9. Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas.  |  L'Imperio, V., et al. 2022. Eur J Immunol. 52: 1350-1361. PMID: 35554927
10. Heterogeneous Surface CD79b Expression in Aggressive B-Cell Lymphomas Assessed by Flow Cytometry on Lymph Node Biopsies.  |  Maiolo, E., et al. 2024. Cancers (Basel). 16: PMID: 39682155

The preferred CD79B antibody is CD79B Antibody (B29/123): sc-53210.